David Klein

MD, PhD, Vice President, Endocrinology and Diabetes, Global Product Development

David is board certified in endocrinology and pediatrics, with a PhD in biochemistry. He came to industry after 25 years’ experience in academic patient care, clinical and basic science research. His research program involved diabetic complications, with basic research into the role of extracellular matrix in diabetic kidney disease and clinical research including the pivotal Diabetes Control and Complications Trial or DCCT, which proved the role glucose control in their onset and progression in humans. The results of his continuously funded studies in diabetes and general endocrinology, including childhood obesity prevention, have been published in the highest rated medical journals.

Prior to joining PPD in June 2018, David was senior director of clinical development at MannKind Corporation where he led the inhaled insulin Afrezza Phase II-III approval program, including Food and Drug Administration (FDA) interactions on his protocol revisions, product labeling, and study timelines. His pharmaceutical career began in 2014 as senior medical director for a leading contract research organization.

David’s diabetes pharmaceutical research experience includes participation in all phases of investigation product development for the treatment of pediatric and adult subjects with types 1 and 2 diabetes, including a wide spectrum of antidiabetic drug classes, treatments for diabetic complications, cardiovascular outcome trials in diabetic and hyperlipidemic subjects, insulin delivery systems (pump, closed loop), insulin clamp studies and continuous glucose monitoring (CGM) devices.

David has extensive clinical research and patient care expertise in general endocrinology, with understanding of adrenal disease, growth disorders, bone metabolism, and rare diseases in pediatrics. He was principal investigator and lead author on obesity intervention (anti-psychotic induced weight gain) and prevention trials (community-based interventions, Saipan and Cincinnati, OH). In addition, he is involved in metabolic rare disease, hyperlipidemia, and non-alcoholic steatohepatitis (NASH) drug development trials.

David has served on numerous grant review, editorial, and consensus development committees.